6 reports of this reaction
5.6% of all OCTINOXATE reports
#7 most reported adverse reaction
HYPERTHYROIDISM is the #7 most commonly reported adverse reaction for OCTINOXATE, manufactured by ALTONA COSMETICS TECHNOLOGY SANAYI VE TICARET ANONIM SIRKETI. There are 6 FDA adverse event reports linking OCTINOXATE to HYPERTHYROIDISM. This represents approximately 5.6% of all 107 adverse event reports for this drug.
Patients taking OCTINOXATE who experience hyperthyroidism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTHYROIDISM is moderately reported among OCTINOXATE users, representing a notable but not dominant share of adverse events.
In addition to hyperthyroidism, the following adverse reactions have been reported for OCTINOXATE:
The following drugs have also been linked to hyperthyroidism in FDA adverse event reports:
HYPERTHYROIDISM has been reported as an adverse event in 6 FDA reports for OCTINOXATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTHYROIDISM accounts for approximately 5.6% of all adverse event reports for OCTINOXATE, making it a notable side effect.
If you experience hyperthyroidism while taking OCTINOXATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.